Updates for NABI AEZS CORT ABIO and ZCLS

Mar 09, 2011 No Comments by

Nabi Biopharmaceuticals (Nasdaq:NABI) said yesterday that they expect final data in the first of the two NicVAX Phase III clinical trials for for the treatment of nicotine addiction in 2H 2011.

Aeterna Zentaris Inc. (NASDAQ: AEZS) and Yakult Honsha Co., Ltd. announced the signing of a development, commercialization and licensing agreement for the development, registration and marketing of perifosine. Under the terms of the agreement, Aeterna Zentaris will receive an initial 6 million Euro (US$ 8.3 M) upfront payment and will be entitled to receive additional up to 44 million Euro (US$ 60.9 M) payments upon achieving certain pre-established milestones including clinical and regulatory events in Japan. Furthermore, Aeterna Zentaris will be supplying perifosine to Yakult Honsha on a cost-plus-basis and be entitled to receive double-digit royalties on future net sales of perifosine in Japan. Yakult Honsha will be responsible for the development, registration and commercialization in Japan.

Corcept Therapeutics Incorporated (NASDAQ: CORT), reiterated previous guidance that they are on target for an end of March 2011 submission of their NDA for CORLUX in Cushings Syndrome.

ARCA biopharma, Inc. (NASDAQ:ABIO) filed a $50m mixed shelf today. Their current market cap is about $25m.

Zalicus (NASDAQ: ZCLS )is planning to initiate a Phase 2b clinical trial of Synavive for rheumatoid arthritis (RA), the SYNERGY trial, in the second quarter of 2011.

Daily News

About the author

Currently residing in New Zealand and employed in the education industry, Mr. A. Burden holds a M.Com in International Business from the University of Sydney and used these skills together with his passion for investing to establish BioPharmCatalyst in June 2010 as a tool for investing decisions in the US pharmaceutical market. He spends much of his free time mountain biking, playing squash and hiking.
No Responses to “Updates for NABI AEZS CORT ABIO and ZCLS”

Leave a Reply